Clinical trial · Observational
To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients
A Prospective Post Marketing Non Interventional Study to Evaluate the Criteria on Which Renewal of LHRH Analogue Treatment is Made in Patients With Prostate Cancer Locally Advanced or Metastatic.
NCT03017313CI-TRIAL-00052418ANARENcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LHRH analogues | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Percentage of patients for whom the initial LHRH prescription (the prescription at the baseline visit) has been renewed at first follow-up visit (same type, same formulation).
- timeFrame
- First follow-up visit (occurs 3 to 6 months from baseline)
Secondary outcomes (9)
- measure
- Percentage of patients for whom the initial LHRH prescription has been renewed at each visit.
- timeFrame
- Baseline, between 3 to 6 months, 12 months, 18 months and 24 months
- measure
- Percentage of patients having switched from a 3 months to a 6 months and also 6 months to 3 months formulation at each visit.
- timeFrame
- Baseline, between 3 to 6 months, 12 months, 18 months and 24 months
- measure
- Percentage of patients starting a 6-month formulation at baseline.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult men diagnosed of locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy with a 3 or 6 month LHRH analogue including those requiring neo-adjuvant or adjuvant androgen deprivation therapy in association with radiotherapy * Patients having provided written informed consent * Patients mentally fit for completing a self-administrated questionnaire Exclusion Criteria: * Patients participating in another clinical study at the time of inclusion * Patients with another severe malignant disease * Life expectancy of less than 12 months * Patients already treated with a LHRH analogue within the last year
References
Publications (0)
Data not yet available
No reference posted for this study.